Intellia Therapeutics (NTLA) announced that it has commenced an underwritten public offering of $150M of shares of its common stock. All of the shares in the proposed offering are to be sold by Intellia. Jefferies, Goldman Sachs & Co. and Citigroup are acting as joint book-running managers for the proposed offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target raised to $30 from $27 at Chardan
- Intellia Therapeutics price target raised to $35 from $29 at Leerink
- Intellia Therapeutics price target raised to $20 from $19 at BofA
- Intellia Therapeutics price target raised to $15 from $11 at Morgan Stanley
- Intellia Therapeutics price target raised to $13 from $7 at Baird